Abstract
Toll-like receptors (TLRs) have been identified as a major class of pattern-recognition receptors. Recognition of pathogen-associated molecular patterns (PAMPs) by TLRs, either alone or in heterodimerization with other TLR or non-TLR receptors, induces signals responsible for the activation of innate immune response. Recent studies have demonstrated a crucial involvement of TLRs in the recognition of fungal pathogens such as Candida albicans, Aspergillus fumigatus and Cryptococcus neoformans. By studying fungal infection in knock-out mice deficient in either TLRs or TLRassociated adaptor molecules, it appeared that specific TLRs such as TLR2 and TLR4 play differential roles in the activation of the various arms of the innate immune response. Recent data also suggest that TLRs offer escape mechanisms to certain pathogenic microorganisms, especially through TLR2-driven induction of antiinflamatory cytokines. These recent developments provide crucial information for understanding the mechanisms of fungal recognition by cells of the immune system, and provide hope for designing new therapeutical approaches to fungal infections.
Keywords: Candida albicans, immunosuppression, pneumonia, TLR4 interaction, Cryptococcus neoformans
Current Pharmaceutical Design
Title: Recognition of Fungal Pathogens by Toll-Like Receptors
Volume: 12 Issue: 32
Author(s): Mihai G. Netea, Gerben Ferwerda, Chantal A.A. van der Graaf, Jos W. M. Van der Meer and Bart Jan Kullberg
Affiliation:
Keywords: Candida albicans, immunosuppression, pneumonia, TLR4 interaction, Cryptococcus neoformans
Abstract: Toll-like receptors (TLRs) have been identified as a major class of pattern-recognition receptors. Recognition of pathogen-associated molecular patterns (PAMPs) by TLRs, either alone or in heterodimerization with other TLR or non-TLR receptors, induces signals responsible for the activation of innate immune response. Recent studies have demonstrated a crucial involvement of TLRs in the recognition of fungal pathogens such as Candida albicans, Aspergillus fumigatus and Cryptococcus neoformans. By studying fungal infection in knock-out mice deficient in either TLRs or TLRassociated adaptor molecules, it appeared that specific TLRs such as TLR2 and TLR4 play differential roles in the activation of the various arms of the innate immune response. Recent data also suggest that TLRs offer escape mechanisms to certain pathogenic microorganisms, especially through TLR2-driven induction of antiinflamatory cytokines. These recent developments provide crucial information for understanding the mechanisms of fungal recognition by cells of the immune system, and provide hope for designing new therapeutical approaches to fungal infections.
Export Options
About this article
Cite this article as:
Netea G. Mihai, Ferwerda Gerben, van der Graaf A.A. Chantal, Van der Meer M. Jos W. and Kullberg Bart Jan, Recognition of Fungal Pathogens by Toll-Like Receptors, Current Pharmaceutical Design 2006; 12 (32) . https://dx.doi.org/10.2174/138161206778743538
DOI https://dx.doi.org/10.2174/138161206778743538 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Roles for G-Quadruplexes in Mitochondria
Current Medicinal Chemistry Licensed DNA Vaccines against Infectious Hematopoietic Necrosis Virus (IHNV)
Recent Patents on DNA & Gene Sequences Impact of the Transfersome Delivered Human Growth Hormone on the Dermal Fibroblast Cells
Current Pharmaceutical Biotechnology The Protective Function of Human C-reactive Protein in Mouse Models of Streptococcus pneumoniae Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets Mammaglobin-Based Strategies for Treatment of Breast Cancer
Current Cancer Drug Targets Early Pathogenesis of Atherosclerosis: The Childhood Obesity
Current Pharmaceutical Design Common Genetic Variants of the Mitochondrial Trafficking System and Mitochondrial Uncoupling Proteins Affect the Development of Two Slowly Developing Demyelinating Disorders, Leukoaraiosis and Multiple Sclerosis
Current Medicinal Chemistry Whole Embryo Culture: An Important Tool in Developmental Toxicology Today
Current Pharmaceutical Design Advances in Allergen-Specific Immunotherapy
Current Drug Targets Nanotechnology and Atherosclerosis Imaging: Emerging Diagnostic and Therapeutic Applications
Recent Patents on Cardiovascular Drug Discovery Mitochondrial Injury and Targeted Intervention in Septic Cardiomyopathy
Current Pharmaceutical Design Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in Oncology: Review of the Literature
Reviews on Recent Clinical Trials Structure, Biology, and Therapeutic Implications of Pegylated Interferon Alpha-2b
Current Pharmaceutical Design Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy
Mini-Reviews in Medicinal Chemistry Erythropoietin in Stroke Therapy: Friend or Foe
Current Medicinal Chemistry A QSAR Study on Some Series of Anti-Hepatitis C Virus (HCV) Agents
Letters in Drug Design & Discovery Immunotoxins in the Treatment of Hematologic Malignancies
Current Drug Targets ACKNOWLEDGEMENTS TO CONTRIBUTORS
Recent Patents on Inflammation & Allergy Drug Discovery Gastric Mucosal Protection: From Prostaglandins to Gene-Therapy
Current Medicinal Chemistry ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry